Education
About Us
Working with TipRanks
Follow Us
Livzon Pharmaceutical Group Class H (HK:1513)
:1513
Total Valuation
Livzon Pharmaceutical Group has a market cap or net worth of HK$32.72B. The enterprise value is HK$25.07B.
Market CapHK$32.72B
Enterprise ValueHK$25.07B
Share Statistics
Livzon Pharmaceutical Group has 299,807,130 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding299,807,130
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Livzon Pharmaceutical Group’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 12.11%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)12.11%
Return on Capital Employed (ROCE)0.17
Revenue Per Employee1.30M
Profits Per Employee254.16K
Employee Count9,067
Asset Turnover0.48
Inventory Turnover2.04
Valuation Ratios
The current PE Ratio of Livzon Pharmaceutical Group is 11.9. Livzon Pharmaceutical Group’s PEG ratio is 1.73.
PE Ratio11.9
PS Ratio2.02
PB Ratio1.72
Price to Fair Value1.72
Price to FCF9.88
Price to Operating Cash Flow12.19
PEG Ratio1.73
Income Statement
In the last 12 months, Livzon Pharmaceutical Group had revenue of 11.81B and earned 2.06B in profits. Earnings per share was 2.24.
Revenue11.81B
Gross Profit7.73B
Operating Income2.84B
Pretax Income2.81B
Net Income2.06B
EBITDA3.47B
Earnings Per Share (EPS)2.24
Cash Flow
In the last 12 months, operating cash flow was 1.69B and capital expenditures -386.75M, giving a free cash flow of 1.81B billion.
Operating Cash Flow1.69B
Free Cash Flow1.81B
Free Cash Flow per Share6.02
Dividends & Yields
Livzon Pharmaceutical Group pays an annual dividend of HK$1.199, resulting in a dividend yield of 3.87%
Dividend Per ShareHK$1.199
Dividend Yield3.87%
Payout Ratio92.06%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.70
52-Week Price Change19.84%
50-Day Moving Average32.04
200-Day Moving Average30.94
Relative Strength Index (RSI)46.28
Average Volume (3m)612.93K
Important Dates
Livzon Pharmaceutical Group upcoming earnings date is Mar 26, 2026, TBA (Confirmed).
Last Earnings DateOct 23, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
Livzon Pharmaceutical Group as a current ratio of 2.15, with Debt / Equity ratio of 33.36%
Current Ratio2.15
Quick Ratio1.89
Debt to Market Cap0.16
Net Debt to EBITDA-1.99
Interest Coverage Ratio32.10
Taxes
In the past 12 months, Livzon Pharmaceutical Group has paid 501.66M in taxes.
Income Tax501.66M
Effective Tax Rate0.18
Enterprise Valuation
Livzon Pharmaceutical Group EV to EBITDA ratio is 4.87, with an EV/FCF ratio of 7.02.
EV to Sales1.43
EV to EBITDA4.87
EV to Free Cash Flow7.02
EV to Operating Cash Flow5.68
Balance Sheet
Livzon Pharmaceutical Group has HK$10.61B in cash and marketable securities with HK$3.51B in debt, giving a net cash position of HK$7.10B billion.
Cash & Marketable SecuritiesHK$10.61B
Total DebtHK$3.51B
Net CashHK$7.10B
Net Cash Per ShareHK$23.68
Tangible Book Value Per ShareHK$15.39
Margins
Gross margin is 64.40%, with operating margin of 24.08%, and net profit margin of 17.45%.
Gross Margin64.40%
Operating Margin24.08%
Pretax Margin23.76%
Net Profit Margin17.45%
EBITDA Margin29.38%
EBIT Margin24.51%
Analyst Forecast
The average price target for Livzon Pharmaceutical Group is HK$37.21, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price TargetHK$37.21
Price Target Upside20.25% Upside
Analyst ConsensusModerate Sell
Analyst Count1
Revenue Growth Forecast-0.45%
EPS Growth Forecast9.00%